Healthcare
This sector includes biotechnology, pharmaceuticals, research services, home healthcare, hospitals, long-term-care facilities, and medical equipment and supplies. Also include pharmaceutical retailers and companies which provide health information services. Companies in this sector include AstraZeneca, Pfizer, and Roche Holding, Walgreens Boots Alliance, and Cerner Corp.
Market Cap
6.821T
Market Weight
10.09%
Industries
11
Companies
1200
Healthcare S&P 500 ^GSPC
Loading Chart for Healthcare
DELL

Day Return

Sector
0.29%
S&P 500
0.02%

YTD Return

Sector
7.76%
S&P 500
25.48%

1-Year Return

Sector
16.52%
S&P 500
35.56%

3-Year Return

Sector
0.70%
S&P 500
27.81%

5-Year Return

Sector
62.37%
S&P 500
93.29%

Note: Sector performance is calculated based on the previous closing price of all sector constituents

Industries in This Sector

Select an Industry for a Visual Breakdown

IndustryMarket WeightYTD Return
All Industries
100.00%
7.76%
Drug Manufacturers - General
33.29%
11.09%
Healthcare Plans
13.22%
-0.71%
Medical Devices
12.49%
5.94%
Biotechnology
11.70%
2.76%
Diagnostics & Research
10.73%
1.24%
Medical Instruments & Supplies
7.73%
25.86%
Medical Care Facilities
3.06%
21.72%
Drug Manufacturers - Specialty & Generic
2.76%
-0.66%
Medical Distribution
2.51%
20.46%
Health Information Services
2.38%
26.29%
Pharmaceutical Retailers
0.12%
-63.98%

Note: Percentage % data on heatmap indicates Day Return

Largest Companies in This Sector

View More
Name
Last Price
1Y Target Est.
Market Weight
Market Cap
Day Change %
YTD Return
Avg. Analyst Rating
811.81 999.43 11.48% 770.664B -0.86% +39.27%
Buy
605.87 625.10 8.31% 557.572B -1.43% +15.08%
Buy
153.24 175.98 5.50% 368.944B +0.39% -2.23%
Buy
170.35 208.90 4.49% 301.032B -0.43% +9.92%
Buy
98.50 133.43 3.71% 249.17B -0.08% -9.65%
Buy
541.90 657.43 3.09% 207.277B +0.21% +2.09%
Buy
115.74 130.24 2.99% 200.746B -0.60% +5.15%
Buy
536.69 539.24 2.85% 191.158B -0.07% +59.09%
Buy
241.53 288.34 2.60% 174.451B +0.81% +4.40%
Buy
301.44 335.10 2.41% 162.034B +0.87% +4.66%
Buy

Investing in the Healthcare Sector

Start Investing in the Healthcare Sector Through These ETFs and Mutual Funds

ETF Opportunities

View More
Name
Last Price
Net Assets
Expense Ratio
YTD Return
146.83 39.816B 0.09% +7.66%
271.29 20.549B 0.10% +8.21%
100.01 7.244B 0.35% +12.01%
143.80 7.086B 0.45% +5.85%
60.05 4.783B 0.40% +11.27%

Mutual Fund Opportunities

View More
Name
Last Price
Net Assets
Expense Ratio
YTD Return
213.67 45.697B 0.30% +2.18%
90.12 45.697B 0.30% +2.21%
135.66 20.549B 0.10% +8.16%
97.91 14.589B 0.80% +11.11%
97.56 14.589B 0.80% +10.99%

Healthcare Research

View More

Discover the Latest Analyst and Technical Research for This Sector

  • Analyst Report: ConvaTec Group PLC

    Originally spun out of Bristol-Myers Squibb, Convatec designs, manufactures, and markets advanced wound care, ostomy, continence care, and infusion sets for the acute-care hospital and chronic-care home settings. Advanced wound care and ostomy supplies are the largest divisions, accounting for 33% and 29% of total revenue, respectively. Continence care has become a slightly smaller business (21% of revenue) following the decision to exit the acute care market, and infusion sets contribute 17% of consolidated revenue.

    Rating
    Price Target
     
  • Analyst Report: Alcon Inc.

    Alcon is one of the leading visioncare companies in the world. Following nine years as a Novartis subsidiary, it was spun off as a public company in April 2019. Alcon operates in two segments: visioncare and surgical. Visioncare comprises contact lenses, lenscare solutions, and a suite of ocular health products. With brands like Dailies, Total1, and Air Optix, Alcon controls one fourth of the U.S. contact lens market. Surgical comprises intraocular lenses, ophthalmic surgical equipment, and consumables used during surgeries. Its main products include Centurion, a phacoemulsification device used during cataract surgeries, and a portfolio of IOLs including PanOptix and Vivity. Alcon has one of the largest installed bases of eye surgical equipment in the world.

    Rating
    Price Target
     
  • Analyst Report: Novo Nordisk

    Novo Nordisk is a pharmaceutical company based in Denmark. Its key divisions include Diabetes Care, Obesity Care, and Rare Diseases. Key products include Ozempic, Victoza, and insulin for diabetes; Wegovy and Saxenda for obesity; and treatments for rare blood and endocrine disorders. The company has approximately 71,880 employees.

    Rating
    Price Target
     
  • Analyst Report: AstraZeneca PLC

    A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across a number of major therapeutic areas, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.

    Rating
    Price Target
     

From the Community

Healthcare News